全文获取类型
收费全文 | 524篇 |
免费 | 47篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 12篇 |
妇产科学 | 12篇 |
基础医学 | 48篇 |
口腔科学 | 40篇 |
临床医学 | 28篇 |
内科学 | 131篇 |
皮肤病学 | 16篇 |
神经病学 | 16篇 |
特种医学 | 10篇 |
外科学 | 111篇 |
综合类 | 16篇 |
预防医学 | 20篇 |
眼科学 | 13篇 |
药学 | 32篇 |
中国医学 | 10篇 |
肿瘤学 | 52篇 |
出版年
2023年 | 14篇 |
2022年 | 32篇 |
2021年 | 34篇 |
2020年 | 17篇 |
2019年 | 35篇 |
2018年 | 31篇 |
2017年 | 25篇 |
2016年 | 20篇 |
2015年 | 18篇 |
2014年 | 33篇 |
2013年 | 31篇 |
2012年 | 39篇 |
2011年 | 45篇 |
2010年 | 18篇 |
2009年 | 15篇 |
2008年 | 9篇 |
2007年 | 14篇 |
2006年 | 11篇 |
2005年 | 13篇 |
2004年 | 6篇 |
2003年 | 6篇 |
2002年 | 7篇 |
2001年 | 4篇 |
2000年 | 6篇 |
1999年 | 6篇 |
1998年 | 2篇 |
1997年 | 4篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 2篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1991年 | 4篇 |
1990年 | 7篇 |
1989年 | 6篇 |
1988年 | 6篇 |
1987年 | 4篇 |
1985年 | 3篇 |
1984年 | 7篇 |
1976年 | 2篇 |
1970年 | 1篇 |
1941年 | 2篇 |
1940年 | 1篇 |
1939年 | 1篇 |
1938年 | 2篇 |
1937年 | 4篇 |
1936年 | 1篇 |
1932年 | 1篇 |
1929年 | 4篇 |
1927年 | 2篇 |
排序方式: 共有573条查询结果,搜索用时 15 毫秒
561.
H. Zain 《Journal of molecular medicine (Berlin, Germany)》1937,16(39):1351-1352
Ohne Zusammenfassung 相似文献
562.
563.
Senthilmani Rajendran Jian Han Lim Kohgulakuhan Yogalingam Thomas George Kallarakkal Rosnah Binti Zain Ruwan Duminda Jayasinghe Jyotsna Rimal Alexander Ross Kerr Rahmi Amtha Karthikeya Patil Roshan Alex Welikala Ying Zhi Lim Paolo Remagnino John Gibson Wanninayake Mudiyanselage Tilakaratne Chee Sun Liew Yi-Hsin Yang Sarah Ann Barman Chee Seng Chan Sok Ching Cheong 《Oral diseases》2023,29(5):2230-2238
564.
565.
Robert Stuver Steven M. Horwitz Ranjana H. Advani Julie M. Vose Hun Ju Lee Neha Mehta-Shah Jasmine M. Zain Bradley Haverkos Mary Jo Lechowicz Alison J. Moskowitz Luu Q. Pham Elizabeth Leyden Stephen M. Ansell Matthew A. Lunning 《British journal of haematology》2023,202(3):525-529
There remains no one standard induction for nodal-based peripheral T-cell lymphoma (PTCL). We conducted a phase II study of lenalidomide plus CHOEP as a novel induction strategy. Patients received CHOEP at standard doses in combination with 10 mg of lenalidomide on days 1–10 of a 21-day cycle for six cycles of therapy followed by observation, high-dose therapy with autologous stem cell rescue, or maintenance lenalidomide per provider preference. Among 39 patients evaluable for efficacy, the objective response rate after six cycles was 69%, with complete response in 49%, partial response in 21%, stable disease in 0% and progressive disease in 13%. Thirty-two patients (82%) completed full induction, and seven patients (18%) discontinued for toxicity, primarily hematologic. Any grade hematologic toxicity occurred in over 50% of patients, with grade 3 or 4 febrile neutropenia occurring in 35% of patients despite mandated growth factors. With a median followup of surviving patients of 21.3 months, the estimated 2-year progression-free and overall survival were 55% (95% CI 37%–70%) and 78% (95% CI 59%–89%), respectively. In sum, six cycles of lenalidomide plus CHOEP resulted in a modest response rate primarily due to hematologic toxicity, which prevented all patients from completing planned induction. 相似文献
566.
Sajjad Ali Samahir Tariq Khan Hamza Usman Ali Hamza Khan Zain Douba Murtaza Ali 《Clinical Case Reports》2021,9(10)
Radiological imaging plays a vital role in clinically diagnosing TSC. TSC prognosis is largely determined by the severity and the extent of the systems affected by it. TSC patients are symptomatically managed, since no cure is present. Healthcare professionals must frequently check‐up TSC patients who have a lifelong disorder. 相似文献
567.
Faisal Al Malki Bandar El Damanhoury MD Abdallah Othman Zain Alghamdi Majed AlQahtani Amr Madgy Zahir Chouikrat 《Diabetes, obesity & metabolism》2023,25(10):2869-2877
Aim
To evaluate the effectiveness and safety profile of switching to insulin glargine 300 U/mL (Gla-U300) in patients with uncontrolled type 2 diabetes (T2D) on basal insulin in Saudi Arabia.Materials and Methods
We conducted a multicentre retrospective study that retrieved the medical records of adult T2D patients switched to Gla-U300 because of poor glycaemic control on their basal insulin. Data covering 6 months ± 30 days before and after the switch were retrieved.Results
Data from 718 patients were analysed. The mean HbA1c decreased significantly 6 months after switching to Gla-U300, with a mean reduction of 0.7% (95% confidence interval [CI] 0.6%-0.9%; P < .001). The percentage of patients with HbA1c levels of less than 7% increased from 6.4% before switching to 10.3% after switching to Gla-U300. The percentage of patients achieving the predefined individualized HbA1c goal increased from 8.6% before switching to 17.3% after switching to Gla-U300. The mean daily insulin dose decreased from a baseline level of 32.2 (± 14.7) to 31.0 (± 15) U (P = .09). About 36.1 of the patients required adjustment to the initial dose. Gla-300 was well tolerated; 4.5% of the patients experienced overall confirmed or symptomatic hypoglycaemia, compared with 15.3% before switching to Gla-U300. The incidence of severe hypoglycaemia after switching was 0.6% (n = 4 patients), compared with 1% before switching.Conclusions
Real-world evidence supports the effectiveness of switching to Gla-U300 from first-generation basal insulin in T2D in Saudi Arabia. 相似文献568.
Deepa J. Arachchillage Indika Rajakaruna Zain Odho Mike Makris Mike Laffan CA-COVID Investigators 《British journal of haematology》2023,202(3):485-497
Post-discharge thromboprophylaxis in patients admitted with COVID-19 remains controversial. We aimed to determine the impact of thromboprophylaxis on hospital acquired thrombosis (HAT) in patients (≥18 years) discharged following admission for COVID-19 in an observational study across 26 NHS Trusts in the UK (01.04.2020–31.12.2021). Overall, 8895 patients were included to the study: 971 patients were discharged with thromboprophylaxis and propensity score matched (PSM) with a desired ratio of 1:1, from patients discharged without thromboprophylaxis. Patients with heparin induced thrombocytopenia, major bleeding during admission and pregnant women were excluded. As expected from 1:1 PSM, no difference was observed in parameters between the two groups, including duration of hospital stay, except the thromboprophylaxis group had a significantly higher proportion who had received therapeutic dose anticoagulation during admission. There were no differences in the laboratory parameters especially D-dimers between the two groups at admission or discharge. Median duration of thromboprophylaxis following discharge from hospital was 4 weeks (1–8 weeks). No difference was found in HAT in patients discharged with TP versus no TP (1.3% vs. 0.92%, p = 0.52). Increasing age and smoking significantly increased the risk of HAT. Many patients in both cohorts had raised D-dimer at discharge but D-dimer was not associated with increased risk of HAT. 相似文献
569.
570.
Nabihah Haron Senthilmani Rajendran Thomas George Kallarakkal Rosnah Binti Zain Anand Ramanathan Mannil Thomas Abraham Shin Hin Lau Lai Choo Cheng Sherrie Mei Yee Chong Farah Aliya Mohamed Azahar Zuraiza Mohamad Zaini Siew Wui Chan Yet Ching Goh Daniel Lim Juliana Khairi Marzuki Zainal Abidin Zainal Ariff Abdul Rahman Chee Sun Liew Siew Chinn Fong Yi-Hsin Yang Siti Mazlipah Ismail Sok Ching Cheong 《Oral diseases》2023,29(2):380-389